Navigating Global Complexity: Applying ICH E17 to Modern Clinical Trial Biometrics
Clinical trials are no longer local experiments with global ambitions. Increasingly, they are global evidence…
Rare Disease Drug Approvals Accelerate as FDA Clears Three New Orphan Therapies
May 2026 — The U.S. Food and Drug Administration has approved three therapies in May…
𝗙𝗗𝗔’𝘀 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗦𝘁𝗮𝗻𝗰𝗲 𝗼𝗻 𝗕𝗮𝘆𝗲𝘀𝗶𝗮𝗻 𝗠𝗲𝘁𝗵𝗼𝗱𝘀: 𝗪𝗵𝗮𝘁 𝗦𝗽𝗼𝗻𝘀𝗼𝗿𝘀 𝗡𝗲𝗲𝗱 𝘁𝗼 𝗞𝗻𝗼𝘄 𝗶𝗻 𝟮𝟬𝟮𝟲
What we see at the January 2026 draft guidance, which formalizes a major shift: Bayesian…
End of content
End of content